Table 1 Main characteristics of the eligible studies included in the meta-analysis
Author | Year | Country | Patients number | Age (years) | FIGO Stage | Tumor Grade | Tumor type | cut-off value (× 109/L) | Incidence of thrombocytosis (%) | Follow-up time (month) | Primary Outcome | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abu-Zaid [24] | 2017 | Saudi Arabia | 162 | 59 | I–IV | 1–3 | endometrioid | 400 | 8.6 | NR | OS, DFS | 6 |
Andersen [27] | 2017 | Denmark | 218 | 18–80 | I–IV | 1–3 | mixed | 400 | 11.5 | NR | OS, DSS | 6 |
Njølstad [28] | 2013 | Norway | 512 | 28–93 | I–IV | 1–3 | mixed | 390 | 12.3 | 55(0–97) | DFS | 6 |
Kizer [22] | 2015 | USA | 318 | 62 | I–IV | 1–3 | mixed | 400 | 16.7 | NR | DFS, DSS | 6 |
Nakamura [23] | 2016 | Japan | 108 | 60 | I–IV | 1–3 | mixed | 350 | 11.02 | NR | OS, PFS | 6 |
Takahashi [26] | 2017 | Japan | 508 | 58 | I–IV | 1–3 | mixed | 400 | 7 | NR | OS | 6 |
Heng [20] | 2014 | Thailand | 238 | 28–88 | I–IV | 1–3 | mixed | 400 | 18.1 | 59.6(1–98) | OS, DFS | 7 |
Matsuo [19] | 2013 | USA | 516 | 52 | I–IV | 1–3 | mixed | 400 | 15.1 | 43.7 | OS, DFS | 8 |
Gorelick [18] | 2009 | USA | 77 | 65 | I–IV | 1–3 | mixed | 400 | 18.2 | NR | OS | 6 |
Lerner [17] | 2007 | USA | 68 | NR | III-IV | NR | serous | 400 | 12 | NR | OS | 6 |
Moeini [25] | 2017 | USA | 714 | 53.1 | I–IV | 1–3 | mixed | 400 | 24.8 | 28.8 | OS, DFS | 8 |